CombiMatrix Begins Work on $1.9 Million U.S. Army Contract
Dr. Robin Liu, the Principal Investigator of this contract, stated, "Under this contract, we will expand the capabilities of our microfluidic lab-on-a-chip technology which we have integrated with our microarray platform and electrochemical detection. Our goal is to complete development of a self-contained, miniature device that will perform rapid multiplexed nucleic acid amplification and microarray detection in an automated instrument."
“As we have stated before, our work in collaboration with the U.S. Government and various military agencies and departments continues to grow”
"As we have stated before, our work in collaboration with the U.S. Government and various military agencies and departments continues to grow," stated Dr. Amit Kumar, President and CEO of CombiMatrix. "As the military continues to recognize the value and power of our technology for its specific needs, we expect this growth trend to continue. Additionally, all of the development under these military contracts will aid in product development for civilian markets."
CombiMatrix's development programs with the U.S. Government are focused on instrument development along with assays that take advantage of our microarray for multiplexed identification of biothreat agents and other infectious agents. Because the microarray is built on semiconductor electronics, it offers unique flexibility for developing assays for diagnosis and surveillance. In addition, the microarray can be read electrochemically, which eliminates the need for an optical reader and significantly reduces the size and complexity of automated systems. CombiMatrix is developing systems for a broad range of requirements from portable hand-held devices to larger industrial units and microfluidics will play an important role in reducing instrument size while maintaining performance.
CombiMatrix's integrated detection system is targeting potential biothreats such as Bacillus anthracis (Anthrax), Yersina pestis (plague), toxins, and other infectious agents that occur naturally or could be used as weapons of mass destruction or in terrorist activity. Rapid identification of these diseases near the site of an outbreak is critical for individual and public health as well as to determine whether or not an act of aggression has occurred. In addition, military personnel need highly accurate and easy to use systems for detection in various battlefield scenarios.
ABOUT ACACIA RESEARCH CORPORATION
Acacia Research Corporation comprises two operating groups, Acacia Technologies group and CombiMatrix group.
The CombiMatrix group is developing a platform technology to rapidly produce customizable arrays, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. The CombiMatrix group's technology has a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences and nanotechnology.
The Acacia Technologies group develops, acquires, and licenses patented technologies. Acacia controls 46 patent portfolios covering technologies used in a wide variety of industries including audio/video enhancement & synchronization, broadcast data retrieval, computer memory cache coherency, credit card fraud protection, database management, data encryption & product activation, digital media transmission (DMT(R)), digital video production, dynamic manufacturing modeling, enhanced Internet navigation, hearing aid ECS, image resolution enhancement, interactive data sharing, interactive television, interstitial Internet advertising, laptop docking station connectivity, microprocessor enhancement, multi-dimensional bar codes, network data storage, resource scheduling, rotational video imaging and spreadsheet automation.
Acacia Research-Acacia Technologies (Nasdaq:ACTG) and Acacia Research-CombiMatrix (Nasdaq:CBMX) are both classes of common stock issued by Acacia Research Corporation and are intended to reflect the performance of the respective operating groups and are not issued by the operating groups.
Information about the Acacia Technologies group and the CombiMatrix group is available at www.acaciaresearch.com.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.